share_log

We Think Shandong Weigao Group Medical Polymer (HKG:1066) Can Stay On Top Of Its Debt

We Think Shandong Weigao Group Medical Polymer (HKG:1066) Can Stay On Top Of Its Debt

我們認爲山東威高股份醫療聚合物(HKG:1066)可以繼續控制其債務
Simply Wall St ·  09/20 20:12

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. As with many other companies Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) makes use of debt. But is this debt a concern to shareholders?

有人說,作爲投資者,更好地思考風險的方式是關注波動性而不是債務,但禾倫·巴菲特曾經說過'波動性與風險遠非同義詞'。當您評估一個公司的風險時,自然會考慮其資產負債表,因爲債務在一個企業破產時通常會涉及。山東威高股份醫療聚合物公司(HKG:1066)和許多其他公司一樣利用了債務。但這種債務是否會讓股東擔憂呢?

When Is Debt A Problem?

什麼時候負債才是一個問題?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, plenty of companies use debt to fund growth, without any negative consequences. When we think about a company's use of debt, we first look at cash and debt together.

如果公司無法通過自由現金流或以優惠價格發行股票籌集資金,承擔起債務和其他負債的風險就會顯得更加嚴重。最壞的情況是,公司如果無法償付債權人,可能會破產。然而,更普遍(但同樣代價高昂)的情況是,公司不得不以極低價格發行股票,以此來支持其資產負債表。當然,許多公司使用債務來資助其增長,並未產生負面後果。在考慮公司的負債使用時,我們首先看現金和債務這兩個指標。

What Is Shandong Weigao Group Medical Polymer's Net Debt?

山東威高股份醫療聚合物的淨債務是多少?

As you can see below, Shandong Weigao Group Medical Polymer had CN¥4.00b of debt at June 2024, down from CN¥4.20b a year prior. However, its balance sheet shows it holds CN¥7.87b in cash, so it actually has CN¥3.86b net cash.

正如下面所示,山東威高股份醫療聚合物在2024年6月時有40億人民幣的債務,比一年前的42億人民幣減少。然而,其資產負債表顯示,該公司持有78.7億人民幣的現金,因此實際上有38.6億人民幣的淨現金。

big
SEHK:1066 Debt to Equity History September 21st 2024
SEHK:1066債務與權益歷史數據截至2024年9月21日

How Healthy Is Shandong Weigao Group Medical Polymer's Balance Sheet?

山東威高股份醫療聚合物的資產負債表有多健康?

According to the last reported balance sheet, Shandong Weigao Group Medical Polymer had liabilities of CN¥5.96b due within 12 months, and liabilities of CN¥3.95b due beyond 12 months. On the other hand, it had cash of CN¥7.87b and CN¥8.00b worth of receivables due within a year. So it actually has CN¥5.95b more liquid assets than total liabilities.

根據最近公佈的資產負債表,山東威高集團醫療聚合物的短期負債爲人民幣596億元,超過12個月到期的長期債務爲人民幣395億元。 另一方面,其現金爲人民幣787億元,一年內到期的應收賬款爲人民幣800億元。 實際上,其流動資產比總負債高595億元。

This surplus strongly suggests that Shandong Weigao Group Medical Polymer has a rock-solid balance sheet (and the debt is of no concern whatsoever). With this in mind one could posit that its balance sheet means the company is able to handle some adversity. Succinctly put, Shandong Weigao Group Medical Polymer boasts net cash, so it's fair to say it does not have a heavy debt load!

這一盈餘強烈提示山東威高股份醫療聚合物有一個堅實的資產負債表(債務根本不成問題)。鑑於此,人們可以推斷其資產負債表意味着該公司能夠應對一些逆境。簡言之,山東威高股份醫療聚合物擁有淨現金,因此可以說它沒有沉重的債務負擔!

It is just as well that Shandong Weigao Group Medical Polymer's load is not too heavy, because its EBIT was down 24% over the last year. Falling earnings (if the trend continues) could eventually make even modest debt quite risky. There's no doubt that we learn most about debt from the balance sheet. But it is future earnings, more than anything, that will determine Shandong Weigao Group Medical Polymer's ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

山東威高股份醫療聚合物的負擔並不太重,因爲其上一年的EBIt下降了24%。收益下降(如果趨勢持續)最終可能使即使是一丁點債務也具有相當風險。毫無疑問,我們從資產負債表中了解最多關於債務。但更重要的是,未來的收入,而不是其他任何事物,將決定山東威高股份醫療聚合物能否維持健康的資產負債表。因此,如果您想了解專業人士的看法,您可能會發現這份關於分析師盈利預測的免費報告很有趣。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. Shandong Weigao Group Medical Polymer may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. During the last three years, Shandong Weigao Group Medical Polymer produced sturdy free cash flow equating to 60% of its EBIT, about what we'd expect. This free cash flow puts the company in a good position to pay down debt, when appropriate.

但我們最後的考慮也很重要,因爲公司不能用虛擬利潤支付債務;它需要冷硬現金。山東威高股份醫療聚合物的資產負債表上可能有淨現金,但觀察企業將其息稅前收入(EBIT)轉化爲自由現金流的能力以及效率情況同樣令人感興趣,因爲這將影響到其管理債務的需求和能力。在過去三年中,山東威高股份醫療聚合物的自由現金流穩健,相當於其EBIt的60%,這正如我們所期望的。這份自由現金流使得公司有很好的位置來償還債務,當需要時。

Summing Up

總之

While we empathize with investors who find debt concerning, you should keep in mind that Shandong Weigao Group Medical Polymer has net cash of CN¥3.86b, as well as more liquid assets than liabilities. So we don't think Shandong Weigao Group Medical Polymer's use of debt is risky. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. For example - Shandong Weigao Group Medical Polymer has 1 warning sign we think you should be aware of.

雖然我們理解投資者對債務感到擔憂,但您應該記住山東威高股份醫療聚合物的淨現金爲38.6億人民幣,以及資產比負債更具流動性。因此,我們認爲山東威高股份醫療聚合物的債務使用並不冒險。在分析債務水平時,資產負債表是顯而易見的起點。然而,並非所有的投資風險都存在於資產負債表中 - 遠非如此。例如,山東威高股份醫療聚合物有1個預警信號,我們認爲您應該注意。

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

說到底,有時候更容易集中精力關注根本不需要債務的公司。讀者可以免費訪問零淨債務增長股票列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論